HIV Infections Clinical Trials

Birmingham : The University of Alabama at Birmingham Alabama Vaccine Research Clinic

A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 (Human Immunodeficiency Virus-1) Infected Adults on ART

Birmingham : University of Alabama Birmingham NICHD CRS (5096)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Birmingham : University Of Alabama At Birmingham

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Birmingham : The University of Alabama at Birmingham

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Hobson City : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Phoenix : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Phoenix : Phoenix Children's Hospital

Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens

Phoenix : Spectrum Medical Group Updated

Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Phoenix : Spectrum Medical Group

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Phoenix : Spectrum Medical Group

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

View More »

Phoenix : Spectrum Medical Group

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Little Rock : Call for Information (Investigational Site 0004)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Bakersfield : Call for Information (Investigational Site 0014)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Bakersfield : Franco Felizarta, MD

Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects

Bakersfield : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Bakersfield : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Bakersfield : Franco Felizarta, MD

Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

View More »

Beverly Hills : AHF Research Center

A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System

Beverly Hills : Call for Information (Investigational Site 0007)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Garden Grove : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Hayward : Kaiser Permanente

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Hayward : Kaiser Permanente

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Irvine : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Long Beach : Miller Children's Hospital Long Beach NICHD CRS (5093)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Long Beach : Living Hope Clinical Foundation

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Long Beach : VA Long Beach Healthcare System

Pilot Study of Raltegravir Lipodystrophy IISP

Long Beach : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Los Angeles : AIDS Research Alliance

A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 (Human Immunodeficiency Virus-1) Infected Adults on ART

Los Angeles : UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CR (3601)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Los Angeles : USC/Los Angeles County Medical Center NICHD CRS (5048)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Los Angeles : Childrens Hospital Los Angeles NICHD CRS (5090)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Los Angeles : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Los Angeles : UCLA CARE Center CRS (601)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Los Angeles : Anthony Mills MD, Inc Updated

Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Los Angeles : UCLA Center for AIDS Research and Education

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

Los Angeles : Anthony Mills MD Inc

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Los Angeles : Peter J Ruane MD Inc.

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Los Angeles : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Los Angeles : Southern California Permanente Medical Group

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Los Angeles : Anthony Mills, MD Internal Medicine

Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients

Los Angeles : UCLA CARE Center

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

Los Angeles : University of Southern California

Strategic Timing of Antiretroviral Treatment

Los Angeles : UCLA CARE-4-Families (LABAC CRS)

Strategic Timing of Antiretroviral Treatment

Los Angeles : VA Greater Los Angeles Healthcare System

Strategic Timing of Antiretroviral Treatment

Los Angeles : Peter J. Ruane, Inc.

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Los Angeles : Peter J. Ruane, MD, Inc.

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Los Angeles : Anthony Mills MD Inc

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Los Angeles : Anthony Mills MD Inc

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Los Angeles : Kaiser Permanente - Los Angeles Medical Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Los Angeles : Kaiser Permanente Los Angeles

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Newport Beach : Call for Information (Investigational Site 0025)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Newport Beach : Orange Coast Medical Group

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

Oakland : East Bay AIDS Center Medical Group

Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Oakland : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Oakland : East Bay AIDS Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Orange : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Orange : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Palm Desert : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Palm Springs : Desert Medical Group Inc.

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Sacramento : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Sacramento : UCDavis Research Office at CARES

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

Sacramento : Kaiser Permanente - Sacramento

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Sacramento : Kaiser Permanente Medical Group

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

San Diego : Univ of California, San Diego (4601)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

San Diego : Ucsd, Avrc Crs (701)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

San Diego : La Playa Medical Group and Clinical Research

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

San Diego : Ucsd Antiviral Research Center

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

San Diego : UCSD Mother-Child-Adolescent Program

Strategic Timing of Antiretroviral Treatment

San Diego : Naval Medical Center San Diego

Strategic Timing of Antiretroviral Treatment

San Diego : La Playa Medical Group and Clinical Research

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

San Diego : La Playa Medical Group and Clinical Research

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

San Francisco : Call for Information (Investigational Site 0002)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

San Francisco : Univiversity of California San Francisco NICHD CRS (5091)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

San Francisco : University of California San Francisco - San Francisco General Hospital

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

San Francisco : Quest Clinical Research

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

San Francisco : Metropolis Medical

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

San Francisco : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

San Francisco : San Francisco General Hospital

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

San Francisco : Kaiser Permanente Medical Center

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

San Francisco : Quest Clinical Research

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

San Francisco : Kaiser Permanente Medical Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

San Francisco : University of California, San Francisco Updated

The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk

Stanford : Stanford University

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

Stanford : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Torrance : Harbor (UCLA) Medical Center NICHD CRS (5045)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Torrance : Harbor-UCLA Med. Ctr. CRS (603)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Torrance : Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Aurora : University of Colorado, Denver NICHD CRS (5052)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Aurora : University of Colorado Hospital CRS (6101)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Denver : University of Colorado Health Sciences Center

A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication

Denver : Denver Public Health CRS

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Denver : Denver Infectious Disease Consultants, PLLC

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

View More »

Denver : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Denver : APEX Research LLC

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Denver : Apex Research, LLC

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Lafayette : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Glastonbury : Call for Information (Investigational Site 0018)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

New Haven : Yale University School of Medicine

Pilot Study of a Raltegravir Based NRTI Sparing Regimen

New Haven : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

New Haven : Yale University School of Medicine

Strategic Timing of Antiretroviral Treatment

New Haven : Yale University School of Medicine

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

View More »

Norwalk : Circle CARE Center, LLC

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

Norwalk : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

West Haven : Va Connecticut Healthcare System

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Wilmington : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Washington : Howard University Washington, DC NICHD CRS (5044)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Washington : Washington Hospital Center NICHD CRS (5023)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Washington : Children's National Med. Ctr. Washington DC NICHD CRS (5015)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Washington : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Washington : Georgetown University CRS (GU CRS) (1008)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

View More »

Washington : Georgetown University

Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients

Washington : Dupont Circle Physician's Group

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Washington : Whitman-Walker Health

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Washington : George Washington University Medical Faculty Associates

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Washington : Children'S National Medical Center

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Washington : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Washington : Georgetown University Hospital

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Washington : Whitman-Walker Clinic

SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

Washington : Georgetown University

Strategic Timing of Antiretroviral Treatment

Washington : Washington DC VA Medical Center

Strategic Timing of Antiretroviral Treatment

Washington : George Washington University Medical Center

Strategic Timing of Antiretroviral Treatment

Washington : Dupont Circle Physicians Group, P.C.

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Washington : Capital Medical Associates, P.C.

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Washington : Whitman Walker Clinic

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Washington : Whitman-Walker Health

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Washington : Capital Medical Associates, PC

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Washington : Medical Faculty Associates, Inc.

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Washington : Dupont Circle Physicians Group

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Daytona Beach :

A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women

Daytona Beach : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Fort Lauderdale : South Florida CDC Ft. Lauderdale NICHD CRS (5055)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Fort Lauderdale : Therafirst Medical Centers

Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

Fort Lauderdale : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

View More »

Fort Lauderdale : Gary J. Richmond, MD PA Updated

Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Fort Lauderdale : Gary J. Richmond,M.D., P.A.

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Fort Lauderdale : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Fort Lauderdale : TheraFirst Medical Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Fort Lauderdale : Gary J. Richmond,M.D.,P.A.

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Fort Lauderdale : Gary Richmond, MD, PA, Inc.

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Fort Myers : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Fort Pierce : Call for Information (Investigational Site 0021)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Fort Pierce : Midway Immunology and Research Center

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Fort Pierce : Midway Immunology and Research Center

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Fort Pierce : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Fort Pierce : Midway Immunology & Research Center, LLC

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Fort Pierce : Midway Immunology and Research Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Jacksonville : Univ. of Florida Jacksonville NICHD CRS (5051)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Jacksonville : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Jacksonville : University of Florida, Jacksonville

Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Jacksonville : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Jacksonville : University of Florida Health Services Center

Strategic Timing of Antiretroviral Treatment

Jacksonville : University of Florida, Jacksonville

Strategic Timing of Antiretroviral Treatment

Miami :

A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women

Miami : University of Miami Pediatric Perinatal HIV/AIDS CRS (4201)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Miami : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Miami : AHF - Kinder Medical Group Updated

Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Miami : The Kinder Medical Group

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Miami : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Miami : University Of Miami School Of Medicine

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Miami : University of Miami School of Medicine, AIDS Clinical Research unit

Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects

Miami : University of Miami

Strategic Timing of Antiretroviral Treatment

Miami Beach : Wohlfeiler, Piperato and Associates, LLC

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Miami Beach : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Miami Beach : AIDS Healthcare Foundation

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Orlando : Call for Information (Investigational Site 0020)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Orlando : Call for Information (Investigational Site 0022)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Orlando : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Orlando : Orlando Immunology Center

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

Orlando : Orlando Immunology Center

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Orlando : Idocf/Valuhealthmd, Llc

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Orlando : Orlando Immunology Center

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Orlando : IDOCF/ValuhealthMD

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Orlando : Orlando Immunology Center

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Orlando : Orlando Immunology Center

Strategic Timing of Antiretroviral Treatment

Orlando : Orange County Health Department/Hug Me

Strategic Timing of Antiretroviral Treatment

Orlando : Orlando Immunology Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Orlando : Idocf/Valuhealthmd

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Orlando : Orlando Immunology Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Orlando : IDOCF/ValuHealthMD, LLC

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Pensacola : Infectious Diseases Associates NW FL, PA

Strategic Timing of Antiretroviral Treatment

Pensacola : Infectious Diseases Associates of NW FL

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Pensacola : Infectious Diseases Associates

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Port St. Lucie :

A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women

Safety Harbor : AHF Health Positive - Tampa Bay

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Safety Harbor : Barry M. Rodwick, M. D.

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

St. Petersburg : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

St. Petersburg : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Tampa : Tampa General Hospital NICHD CRS (5111)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Tampa : USF - Tampa NICHD CRS (5018)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Tampa : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Tampa : University of South Florida - Department of Pediatrics

Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Tampa : St. Joseph's Hospital Comprehensive Research Institute

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Tampa : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Tampa : USF Health - HIV Clinical Research Unit

Strategic Timing of Antiretroviral Treatment

Tampa : Infectious Disease Research Institute Inc.

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Tampa : Infectious Disease Research Institute Inc.

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Tampa : St. Joseph's Comprenhensive Research Inisitute

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Tampa : The University of South Florida

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Vero Beach : Treasure Coast Infectious Disease Consultants

Strategic Timing of Antiretroviral Treatment

Vero Beach : AIDS Research and Treatment Center of the Treasure Coast

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Vero Beach : AIDS Research and Treatment Center of the Treasure Coast

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

West Palm Beach : Call for Information (Investigational Site 0019)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

West Palm Beach :

A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women

Atlanta : Call for Information (Investigational Site 0010)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Atlanta : AIDS Research Consortium of Atlanta

A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 (Human Immunodeficiency Virus-1) Infected Adults on ART

Atlanta : Grady Infectious Diseases Program

Kaletra Sex/Gender Pharmacokinetics (PK) Study: A Switch From Twice Daily to Once Daily Lopinavir/Ritonavir

Atlanta : AIDS Research Consortium of Atlanta

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Atlanta : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

View More »

Atlanta : Emory University

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Atlanta : Atlanta ID Group, PC

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Atlanta : Atlanta ID Group, PC

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Atlanta : AIDS Research Consortium of Atlanta

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Atlanta : AIDS Research Consortium of Atlanta

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Augusta : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Decatur : Call for Information (Investigational Site 0015)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Decatur : Infectious Disease Specialists of Atlanta Updated

Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Decatur : Infectious Disease Specialists of Atlanta

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Decatur : Infectious Disease Specialists of Atlanta

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Decatur : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Decatur : Infectious Disease Specialist of Atlanta

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Decatur : Infectious Disease Specialist of Atlanta

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Douglasville : American Red Cross

Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

Macon : Mercer University Mercer Medicine

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Macon : Mercer University School of Medicine

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Macon : Mercer University

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Marietta : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Riverdale : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Savannah : Call for Information (Investigational Site 0003)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Savannah : Chatham County Health Daprtment

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Savannah : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Honolulu : University of Hawaii - Hawaii Center for AIDS

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Chicago : The Ruth M. Rothstein CORE Center

A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication

Chicago : Call for Information (Investigational Site 0009)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Chicago : Chicago Children's CRS (4001)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Chicago : Rush University Cook County Hospital NICHD CRS (5083)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Chicago : Northwestern University CRS (2701)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

View More »

Chicago : Rush University - Stroger Hospital of Cook County

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

Chicago : University of Chicago

Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Chicago : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Chicago : Lurie Children's Hospital

Strategic Timing of Antiretroviral Treatment

Chicago : Mt. Sinai Hospital

Strategic Timing of Antiretroviral Treatment

Chicago : University of Illinois at Chicago

Strategic Timing of Antiretroviral Treatment

Chicago : Carolinas Medical Center--Myers Park Infectious Disease Clinic

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Chicago : Ruth M. Rothstein CORE Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Chicago : Howard Brown Health Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Chicago : The Ruth M. Rothstein CORE Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Chicago : Howard Brown Health Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Peoria : Call for Information (Investigational Site 9001)

Isentress Re-examination Study (MK-0518-115 AM1)

Springfield : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Iowa City : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Overland Park : GSK Investigational Site

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

Lexington : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

New Orleans : Tulane University NICHD CRS (5095)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

New Orleans : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

New Orleans : Tulane University Medical Center

Strategic Timing of Antiretroviral Treatment

Baltimore : GSK Investigational Site

A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Escalating Doses of GSK2838232 in Healthy Subjects

Baltimore : Johns Hopkins University NICHD CRS (5092)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Baltimore : University of Maryland NICHD CRS (5094)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Baltimore : University of Maryland, School of Medicine

Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

Baltimore : Evelyn Jordan Center

Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

View More »

Baltimore : University of Maryland, Institute of Human Virology

R5 Integrase Study in HIV-1 Naive Patients

Bethesda : National Institutes of Health Clinical Center

Strategic Timing of Antiretroviral Treatment

Bethesda : Walter Reed National Military Medical Center

Strategic Timing of Antiretroviral Treatment

Lutherville : Johns Hopkins University

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Silver Spring : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Boston : Children's Hospital of Boston NICHD CRS (5009)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Boston : Boston Medical Center Ped. HIV Program NICHD CRS (5011)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Boston : Brigham and Women's Hospital NICHD CRS (5110)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Boston : Brigham and Women's Hosp. ACTG CRS (107)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Boston : Massachusetts General Hospital ACTG CRS (101)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

View More »

Boston : Beth Israel Deaconess Med. Ctr., ACTG CRS (103)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Boston : Community Research Initiative of New England

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Boston : Brigham and Women's Hospital

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Boston : Massachusetts General Hospital

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Boston : Community Research Initiative of New England

Strategic Timing of Antiretroviral Treatment

Boston : Boston Medical Center

Strategic Timing of Antiretroviral Treatment

Boston : Community Research Initative

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Boston : Brigham & Women's Hospital

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Boston : Community Research Initiative of New England

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Boston : Massachusetts General Hospital

Subclinical Atherosclerosis in HIV-infected Patients

Springfield : The Research Institute

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Springfield : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Springfield : The Research Institute

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

West Springfield : The Research Institute

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Worcester : WNE Maternal Pediatric Adolescent AIDS CRS (7301)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Ann Arbor : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Berkeley : Be Well Medical Center, P.C. Updated

Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Berkley : Be Well Medical Center

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Berkley : Be Well Medical Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Berkley : Be Well Medical Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

View More »

Detroit : Wayne State University/Children's Hospital of Michigan NICHD CRS (5041)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Detroit : Hutzel Hospital NICHD CRS (5089)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Detroit : Henry Ford Hosp. CRS (31472)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Detroit : Wayne State Univ. CRS

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Detroit : Henry Ford Hospital

Post-Exposure Prophylaxis in Health Care Workers

Detroit : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Detroit : Wayne State University

Strategic Timing of Antiretroviral Treatment

Detroit : Henry Ford Health System

Strategic Timing of Antiretroviral Treatment

Detroit : Henry Ford Health System

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Detroit : Henry Ford Hospital

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

East Lansing : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Grosse Pointe Woods : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Lansing : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Southfield : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

St. Louis : Central West Clinical Research Inc

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Minneapolis : MMRF, Hennepin County Medical Center

Strategic Timing of Antiretroviral Treatment

Minneapolis : Hennepin County Medical Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Minneapolis : Hennepin County Medical Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Rochester : Mayo Clinic

Strategic Timing of Antiretroviral Treatment

Santa Fe : Southwest CARE Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

St. Louis : Call for Information (Investigational Site 0006)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

St. Louis : Washington U CRS (2101)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

St. Louis : Washington University School of Medicine

Heart Function in HIV-Negative Children Exposed to HIV and HAART

St. Louis : Central West Clinical Research Updated

Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

St. Louis : Central West Clinical Research, Inc.

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

View More »

St. Louis : Southampton Healthcare, Inc.

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

St. Louis : Southampton Healthcare, Inc.

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

St. Louis : Central West Clinical Research, Inc.

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

St. Louis : St. Louis University Infectious Diseases Clinic

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

St. Louis : Saint Louis University

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Omaha : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Camden : Cooper Univ. Hosp. CRS (31476)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Camden : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Camden : Cooper University Hospital

Strategic Timing of Antiretroviral Treatment

Hillsborough : ID Care

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Hillsborough : ID Care

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

View More »

Long Branch : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Morristown : Morristown Memorial Hospital

RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART)

Neptune : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Newark : Call for Information (Investigational Site 0008)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Newark : New Jersey Medical School CRS (2802)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Newark : New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Newark : New Jersey Medical School

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Newark : Saint Michael's Medical Center

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Newark : Saint Michael'S Medical Center

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Newark : New Jersey Medical School Adult Clinical Research Center

Strategic Timing of Antiretroviral Treatment

Newark : Saint Michael's Medical Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Somers Point : South Jersey Infectious Disease

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Somers Point : South Jersey Infectious Disease

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Somers Point : South Jersey Infectious Disease

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Santa Fe : Southwest CARE Center

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

Santa Fe : Southwest C.A.R.E. Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Albany : Upstate Infectious Diseases Associates

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Albany : Albany Medical College

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Bronx :

A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women

Bronx : Jacobi Med. Ctr. Bronx NICHD CRS (5013)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Bronx : Bronx-Lebanon Hospital IMPAACT CRS (6901)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

View More »

Bronx : Montefiore Medical Center

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Bronx : Jacobi & North Central Bronx Hospitals

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

Bronx : James J Peters Vamc

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Bronx : Montefiore Medical Center

Strategic Timing of Antiretroviral Treatment

Bronx : Bronx-Lebanon Hospital Center

Strategic Timing of Antiretroviral Treatment

Bronx : Jacobi Medical Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Bronx : Montefiore Medical Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Buffalo : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Ithaca : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Manhasset : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Manhasset : North Shore University Hospital - Division of Infectious Diseases

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Manhasset : North Shore University Hospital - Division of Infectious Diseases

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Monticello : Upper Delaware Valley Infectious Diseases, Pc

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Mount Vernon : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Mount Vernon : Greiger Clinic

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Mt Vernon : Greiger Clinic

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

New York : Columbia IMPAACT CRS (4101)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

New York : Metropolitan Hospital NICHD CRS (5003)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

New York : New York University NY NICHD CRS (5012)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

New York : NY Univ. HIV/AIDS CRS (401)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

New York : Cornell CRS (7804)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

New York : Bellevue Hospital

Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

New York : Ricky K Hsu, MD, PC

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

New York : New York University School of Medicine

Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

New York : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

New York : ACRIA

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

New York : Mount Sinai School Of Medicine

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

New York : Weill Cornell Medical College

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

New York : Cornell CRS

Strategic Timing of Antiretroviral Treatment

New York : Chelsea Village Medical

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

New York : Chelsea Village Medical

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Rochester : Strong Memorial Hospital, University of Rochester NICHD CRS (5057)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Rochester : Univ. of Rochester ACTG CRS (1101)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Rochester : University of Rochester

Comparing Raltegravir Genital Tract Distribution in HIV-Infected Men and Women

Rochester : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

South Bronx : Jacobi Medical Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Stony Brook : SUNY Stony Brook NICHD CRS (5040)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Syracuse :

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents

Syracuse : Suny Upstate Medical University

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Valhalla : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Chapel Hill : Call for Information (Investigational Site 0012)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Chapel Hill : University of North Carolina at Chapel Hill

Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera

Chapel Hill : Unc Aids Crs (3201)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Chapel Hill : AIDS Clinical Trials Unit

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

Chapel Hill : University Of North Carolina At Chapel Hill

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

View More »

Chapel Hill : UNC AIDS Clinical Trials Unit

Strategic Timing of Antiretroviral Treatment

Chapel Hill : The University of North Carolina - Chapel Hill

Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Naïve Patients Treated With Darunavir/Ritonavir and Etravirine

Chapel Hill : University of North Carolina AIDS Clinical Trials Unit

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Chapel Hill : University of North Carolina

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Chapel Hill : The University of North Carolina at Chapel Hill

The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART

Charlotte : Carolinas Medical Center

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Charlotte : ID Consultants

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Charlotte : Carolinas Medical Center Myer's Park Clinic

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Charlotte : Infectious Disease Consultants, PA

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Durham : Duke University Medical Center (DUMC) Pediatric CRS (4701)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Durham : Duke Univ. Med. Ctr. Adult CRS (1601)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Durham : Duke University Medical Center

Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Durham : Duke University Medical Center

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

Durham : Duke University

Strategic Timing of Antiretroviral Treatment

Durham : Duke University

Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Naïve Patients Treated With Darunavir/Ritonavir and Etravirine

Durham : Duke University Medical Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Durham : Duke University

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Greensboro : Regional Center for Infectious Disease

Strategic Timing of Antiretroviral Treatment

Greenville : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Huntersville : Rosedale Infectious Diseases

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Huntersville : Rosedale Infectious Diseases

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Huntersville : Rosedale Infectious Disseases

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Raleigh : Wake County Human Services

Strategic Timing of Antiretroviral Treatment

Wilmington : Registry Coordinating Center

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.

Wilmington : GSK Investigational Site

Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects

Winston-Salem : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Winston-Salem : Wake Forest University Health Sciences

Strategic Timing of Antiretroviral Treatment

Cincinnati : Univ. of Cincinnati CRS (2401)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Cincinnati : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Cleveland : Case CRS (2501)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Cleveland : Metro Health CRS (2503)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Cleveland : Case Western Reserve University

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

View More »

Columbus : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Columbus : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Columbus : The Ohio State University Medical Center

Strategic Timing of Antiretroviral Treatment

Toledo : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Oklahoma City : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Portland : The Research and Education Group - Portland

Strategic Timing of Antiretroviral Treatment

Allentown : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Philadelphia : Call for Information (Investigational Site 0016)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Philadelphia : Drexel University College of Medicine

A Study of HIV-infected Subjects Initiating Anti-HIV Drugs for the First Time

Philadelphia : The Children's Hospital of Philadelphia IMPAACT CRS (6701)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Philadelphia : Drexel University College of Medicine

A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

View More »

Philadelphia : Reproductive Research Unit, U of Penn Medical Center

An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots

Philadelphia : Hosp. of the Univ. of Pennsylvania CRS (6201)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Philadelphia : Temple General Internal Medicine

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)

Philadelphia : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Philadelphia : Philadelphia FIGHT

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Philadelphia : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Philadelphia : University of Pennsylvania

Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy

Philadelphia : Division of Infectious Disease and HIV Medicine Partnership Comprehensive Care Practice

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

Philadelphia : Temple University

Strategic Timing of Antiretroviral Treatment

Philadelphia : University of Pennsylvania

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Philadelphia : Thomas Jefferson University

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Philadelphia : University of Pennsylvania

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Pittsburgh : Pitt CRS (1001)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Providence : The Miriam Hospital

A Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV Medication

Providence : The Miriam Hospital

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Providence : The Miriam Hospital

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Charleston : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Columbia : Call for Information (Investigational Site 0001)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Columbia : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Columbia : University of South Carolina School of Medicine

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Memphis :

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents

Memphis : St. Jude/UTHSC CRS (6501)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Memphis : St. Jude Children's Research Hospital Updated

Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Memphis : St. Jude Children's Research Hospital

Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Memphis : St. Jude Children's Research Hospital

Strategic Timing of Antiretroviral Treatment

Addison : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Austin : Central Texas Clinical Research

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Austin : Central Texas Clinical Research

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Austin : Central Texas Clinical Research

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Austin : Central Texas Clinical Research

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

View More »

Bellaire : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Dallas : UT Southwestern Medical Center at Dallas

HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)

Dallas : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Dallas : Southwest Infectious Disease Clinical Research, Inc.

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Dallas : Trinity Health and Wellness Center/AIDS Arms, Inc.

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Dallas : AIDS Arms, Inc./Trinity Health & Wellness Center

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Dallas : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Dallas : Ut Southwestern Medical Center

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Dallas : UT Southwestern Clinical Research Unit

Strategic Timing of Antiretroviral Treatment

Dallas : North Texas Infectious Diseases Consultants

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Dallas : Trinity Health and Wellness Center/AIDS Arms, Inc.

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Dallas : Trinity Health & Wellness Center / AIDS Arms, Inc.

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Dallas : North Texas Infectious Diseases Consultants

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Dallas : UT Southwestern Medical Center

Therapeutic Approaches to HAART-Induced Lipodystrophy

Fort Worth : Tarrant County Infectious Disease Associates Updated

Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Fort Worth : Tarrant County Infectious Disease

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Fort Worth : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Fort Worth : University of North Texas Health Science Center

Strategic Timing of Antiretroviral Treatment

Fort Worth : Tarrant County Infectious Disease Associates

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Fort Worth : Tarrant County Infectious Disease Associates

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Harlingen : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Houston : Call for Information (Investigational Site 0017)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Houston : Therapeutic Concepts, PA

A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects

Houston : Texas Children's Hosp. CRS (3801)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Houston : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Houston : Houston AIDS Research Team CRS (31473)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Houston : Gordon E. Crofoot MD, PA Updated

Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Houston : Gordon Crofoot, MD, PA

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

Houston : Gordon Crofoot MD, PA

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Houston : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Houston : Baylor College Of Medicine

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Houston : Texas Children's Hospital

Strategic Timing of Antiretroviral Treatment

Houston : Houston AIDS Research Team CRS

Strategic Timing of Antiretroviral Treatment

Houston : Gordon E. Crofoot, MD, PA

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Houston : Research Access Network

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Houston : Therapeutic Concepts, PA

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Houston : Gordon E. Crofoot, MD, PA

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Houston : Therapeutic Concepts, PA

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Houston : Research Access Network

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Houston : The University of Texas Health Science Center at Houston

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

Longview : DCOL Center for Clinical Research

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Longview : DCOL Center for Clinical Research

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Longview : DCOL Center for Clinical Research

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

San Antonio : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

San Antonio : Alamo Medical Research

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

San Antonio : San Antonio Military Health System

Strategic Timing of Antiretroviral Treatment

Annandale : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Annandale : Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID)

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Annandale : Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID)

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Annandale : Clinical Alliance for Research & Education - Infectious Diseases (CARE-ID)

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Danville : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

View More »

Lynchburg : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Richmond : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Richmond : Virginia Commonwealth Univ. Medical Ctr. CRS (31475)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Richmond : Virginia Commonwealth University

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Richmond : Virginia Commonwealth University

Strategic Timing of Antiretroviral Treatment

Seattle : Seattle Children's Hospital NICHD CRS (5017)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Seattle : University of Washington NICHD CRS (5029)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Seattle : Harborview Medical Center NICHD CRS (5027)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Seattle : University of Washington AIDS CRS (1401)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Seattle : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

View More »

Seattle : Peter Shalit, M.D.

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Seattle : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Seattle : Peter Shalit, MD

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Seattle : Peter Shalit, MD

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Huntington : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Madison : University of Wisconsin Hospital and Clinics

A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease

Madison : University of Wisconsin Hospital and Clinics

Nelfinavir and M8 Drug-Level Monitoring in HIV-1 Infection

Milwaukee : Medical College of Wisconsin

Strategic Timing of Antiretroviral Treatment

Milwaukee : AIDS Resource Center of Wisconsin

Strategic Timing of Antiretroviral Treatment

Buenos Aires : Hospital General de Agudos Buenos Aires Argentina NICHD CRS (5082)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Buenos Aires : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Buenos Aires : Hospital Italiano de Buenos Aires

Strategic Timing of Antiretroviral Treatment

Buenos Aires : Hospital General de Agudos JM Ramos Mejia

Strategic Timing of Antiretroviral Treatment

Buenos Aires : Fundacion IDEAA

Strategic Timing of Antiretroviral Treatment

View More »

Buenos Aires : FUNCEI

Strategic Timing of Antiretroviral Treatment

Buenos Aires : Hospital General de Agudos Teodoro Alvarez

Strategic Timing of Antiretroviral Treatment

Buenos Aires, Bs As : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Bunos Aires : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

C 1249 Abp - Buenos Aires :

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

Ciudad De Buenos Aires : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Cordoba : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Cordoba : Hospital Rawson

Strategic Timing of Antiretroviral Treatment

El Palomar : Hospital Nacional Profesor Alejandro Posadas

Strategic Timing of Antiretroviral Treatment

La Matanza : Hospital Interzonal General de Agudos Dr. Diego Paroissien

Strategic Timing of Antiretroviral Treatment

La Plata : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Prov De Santa Fe : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Rosario : Instituto CAICI

Strategic Timing of Antiretroviral Treatment

Adelaide : Royal Adelaide Hospital

Strategic Timing of Antiretroviral Treatment

Brisbane : Sexual Health and HIV Service - Clinic 2

Strategic Timing of Antiretroviral Treatment

Burwood : Burwood Road General Practice

Strategic Timing of Antiretroviral Treatment

Clayton : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Darlinghurst :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

View More »

Darlinghurst : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Darlinghurst : East Sydney Doctors

Strategic Timing of Antiretroviral Treatment

Darlinghurst : Taylor Square Private Clinic

Strategic Timing of Antiretroviral Treatment

Darlinghurst : St. Vincent's Hospital

Strategic Timing of Antiretroviral Treatment

Darlinghurst : Holdsworth House Medical Practice

Strategic Timing of Antiretroviral Treatment

Darlinghurst Nsw : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Melbourne :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Melbourne : The Alfred Hospital

A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-HBV co-Infected Patients

Melbourne : The Alfred Hospital

HIV-HBV Co-Infection and Liver Disease

Melbourne : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Melbourne : Melbourne Sexual Health Centre

Strategic Timing of Antiretroviral Treatment

Melbourne : The Alfred Hospital

Strategic Timing of Antiretroviral Treatment

Melbourne : Prahran Market Clinic

Strategic Timing of Antiretroviral Treatment

North Ryde : Merck Sharp & Dohme

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Parkville :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Parville : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Perth : Royal Perth Hospital

Strategic Timing of Antiretroviral Treatment

St Kilda : Centre Clinic

Strategic Timing of Antiretroviral Treatment

Sydney :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Sydney : 407 Doctors

Once Daily 3TC, Efavirenz and ddI for HIV Infection

Westmead : Westmead Hospital

Strategic Timing of Antiretroviral Treatment

Graz : Boehringer Ingelheim Investigational Site 6

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Innsbruck : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Salzburg : Boehringer Ingelheim Investigational Site 5

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Vienna : Boehringer Ingelheim Investigational Site 2

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Vienna : Boehringer Ingelheim Investigational Site 3

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

View More »

Vienna : Boehringer Ingelheim Investigational Site 1

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Vienna : Otto-Wagner-Spital SMZ /Baumgartner Hoehe

Strategic Timing of Antiretroviral Treatment

Vienna : University Vienna General Hospital

Strategic Timing of Antiretroviral Treatment

Wels : Boehringer Ingelheim Investigational Site 4

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Antwerp : Institute of Tropical Medicine

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Antwerp : Institute of Tropical Medicine

Strategic Timing of Antiretroviral Treatment

Antwerpen : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Antwerpen : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Brussel : Updated

Telaprevir Open-Label Study in Co-Infected Patients

View More »

Brussels : MSD Belgium BVBA/SPRL

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Brussels : CUB Hopital Erasme- Free University of Brussels

A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects

Brussels : Saint-Pierre University Hospital; Department of Infectious Diseases

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Brussels : Hôpitaux IRIS SUD

Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women

Brussels : Hospital St Pierre

Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

Brussels : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Brussels : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Brussels : Centre Hospitalier Universitaire St. Pierre (C.H.U. St. Pierre)

Strategic Timing of Antiretroviral Treatment

Bruxelles : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Charleroi : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Gent : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Ghent : Universitaire Ziekenhuizen Gent

Strategic Timing of Antiretroviral Treatment

Leuven : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Leuven : Universitair Ziekenhuis Gasthuisberg

Strategic Timing of Antiretroviral Treatment

Liege : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Gaborone : Gaborone Prevention/Treatment Trials CRS (12701)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Belo Horizonte : SOM Federal University Minas Gerais Brazil NICHD CRS (5073)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Campinas : GSK Investigational Site

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Porto Alegre : Hospital Santa Casa NICHD CRS (5098)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Porto Alegre : Hospital Nossa Senhora da Conceicao CRS (12201)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Porto Alegre : GSK Investigational Site

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

View More »

Porto Alegre : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Porto Alegre : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Recife : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Ribeirao Preto :

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

Rio de Janeiro : Hospital dos Servidores Rio de Janeiro NICHD CRS (5072)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Rio de Janeiro : Hospital Geral De Nova Igaucu Brazil NICHD CRS (5097)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Rio de Janeiro : Universidade Federal do Rio de Janeiro NICHD CRS (5071)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Rio de Janeiro : Instituto de Pesquisa Clinica Evandro Chagas (IPEC)

An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin

Rio De Janeiro : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Rio de Janeiro : Ipec/Fiocruz

Strategic Timing of Antiretroviral Treatment

Rio de Janeiro : Hospital Escola Sao Francisco de Assis - UFRJ

Strategic Timing of Antiretroviral Treatment

Rio De Janeiro :

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

Salvador : SEI - Servicos Especializados em Infectologia

Strategic Timing of Antiretroviral Treatment

Sao Paolo : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Sao Paulo : Univ of Sao Paulo Brazil NICHD CRS (5074)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Sao Paulo : Insituto de Infectologia Emilio Ribas NICHD CRS (5075)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Sao Paulo : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Sao Paulo : Lim 56/Hcfmusp

Strategic Timing of Antiretroviral Treatment

Sao Paulo : Instituto de Infectologia Emilio Ribas - IIER

Strategic Timing of Antiretroviral Treatment

Sao Paulo : Centro de Referencia e Treinamento DST/Aids

Strategic Timing of Antiretroviral Treatment

Vitoria : University of Espirito Santo

An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin

Vitoria : Center for Infectious Diseases at the UFES

Strategic Timing of Antiretroviral Treatment

Bobo Dioulasso : Day Hospital, CHU Sanou Souro

Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)

Yaounde : Day Hospital, Central Hospital

Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)

Edmonton : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Halifax : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Kirkland : Merck Frosst Canada

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Montreal : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Montreal : Site Reference ID/Investigator# 75442

Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program

View More »

Montreal : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Montreal : Clinique Medicale L'actuel

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Montreal : Clinique OPUS

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Montreal : Clinique medicale l'Actuel

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Montreal : Immunodeficiency Service Montreal Chest Institute McGill University Health Centre

Trial of Citalopram for the Prevention of Depression

Montréal : Montreal Chest Institute, Immunodeficiency Dept.

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

Montréal : Clinique médicale l'Actuel

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

Montréal : Clinique Médical du Quartier Latin

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

Ottawa : Site Reference ID/Investigator# 77613

Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program

Ottawa : The Ottawa Hospital

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

Ottawa : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Ottawa : The Ottawa Hospital - General Campus

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Ottawa : The Ottawa Hospital

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Toronto : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Toronto : Site Reference ID/Investigator# 79793

Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program

Toronto : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Toronto : Maple Leaf Research

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Toronto : Sunnybrook Health Science Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Toronto : Sunnybrook Health Sciences Centre

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Toronto : Maple Leaf Research

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Vancouver : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Vancouver : Site Reference ID/Investigator# 75438

Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program

Vancouver : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Victoria : Site Reference ID/Investigator# 75440

Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program

Victoria : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Winnipeg : Health Sciences Centre Winnipeg

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Winnipeg : WRHA - Health Sciences Centre Winnipeg

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Santiago : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Santiago : Fundacion Arriaran

Strategic Timing of Antiretroviral Treatment

Beijing : Division of Treatment and Care, NCAIDS, China CDC

A Trial to Compare Raltegravir Versus Nevirapine as Anchor Drug for HIV+ Chinese IDUs on Methadone Maintenance

Plzen : University Hospital Plzen, CZ

Strategic Timing of Antiretroviral Treatment

Prague : Faculty Hospital Na Bulovce, Prague, Czech Rep.

Strategic Timing of Antiretroviral Treatment

Aarhus : Arhus Universitetshospital, Skejby

Strategic Timing of Antiretroviral Treatment

Copenhagen : Rigshospitalet, Department of Infectious Diseases, M5112 CRS

Strategic Timing of Antiretroviral Treatment

Hvidovre : Hvidovre University Hospital, Department of Infectious Diseases CRS

Strategic Timing of Antiretroviral Treatment

Odense : Odense University Hospital

Strategic Timing of Antiretroviral Treatment

Tallinn : West Tallin Central Hospital Infectious Diseases

Strategic Timing of Antiretroviral Treatment

Helsinki : Helsinki University Central Hospital, Div. of Infectious Diseases CRS

Strategic Timing of Antiretroviral Treatment

Besancon : CHU de BESANCON - Hopital Saint Jacques

Strategic Timing of Antiretroviral Treatment

Bobigny : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Bondy : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Bordeaux : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Caen : CHU De Caen, Service de Néphrologie Hémodialyse

Renal Transplantation and Raltegravir in HIV-Infected Patients

View More »

Caen : CHU Cote de Nacre

Strategic Timing of Antiretroviral Treatment

Clamart : Valerie Martinez

Lenalidomide in Kaposi Disease Associated With HIV Infection

Clamart : Hopital Antoine Beclere

Strategic Timing of Antiretroviral Treatment

Creteil : Hôpital Henri Mondor

Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients

Creteil : Hopital Henri Mondor

Strategic Timing of Antiretroviral Treatment

Créteil : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Créteil : Hôpital Henri Mondor, Service de Néphrologie Transplantation

Renal Transplantation and Raltegravir in HIV-Infected Patients

Garches : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Kremlin Bicêtre : Hôpital Kremlin Bicêtre, Service de Néphrologie

Renal Transplantation and Raltegravir in HIV-Infected Patients

Le Kremlin-Bicetre : Hopital de Bicetre

Strategic Timing of Antiretroviral Treatment

LYON Cedex 4 : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Marseille : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Marseille Cedex 09 : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Montpellier Cedex 5 : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Nantes : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Paris : MSD France

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Paris : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Paris : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Paris : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Paris : Hopital Saint-Antoine

Strategic Timing of Antiretroviral Treatment

Paris : Hopital Saint-Louis

Strategic Timing of Antiretroviral Treatment

Paris : Hopital Europeen Georges Pompidou

Strategic Timing of Antiretroviral Treatment

Paris : Groupe Hospitalier Pitie-Salpetriere

Strategic Timing of Antiretroviral Treatment

Paris : Hopital Hotel Dieu

Strategic Timing of Antiretroviral Treatment

Paris : Hopital Cochin CIC de vaccinologie

Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients

Paris : Hôpital Bichat-Claude Bernard

Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients

Paris Cedex 10 : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Paris Cedex 10 : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Paris Cedex 10 : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Paris Cedex 12 : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Paris Cedex 13 : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Paris CEDEX 14 : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Paris cedex 15 : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Paris Cedex 20 : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Paris, 75 : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Pessac : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Pessac Cedex : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Rennes : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Suresnes : Hopital Foch

Strategic Timing of Antiretroviral Treatment

Toulon : Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Service d'infectiologie

IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients

Toulon : Centre Hospitalier Intercommunal de Toulon La Seyne sur mer

IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients

Tourcoing : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Tourcoing : Hopital Gustave Dron

Strategic Timing of Antiretroviral Treatment

Aachen : Site Reference ID/Investigator# 28228

Kaletra in Combination With Antiretroviral Agents

Aachen : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Aachen : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Aachen : Site Reference ID/Investigator# 28521

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

View More »

Berlin :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Berlin : Site Reference ID/Investigator# 47155

Kaletra in Combination With Antiretroviral Agents

Berlin : Site Reference ID/Investigator# 28183

Kaletra in Combination With Antiretroviral Agents

Berlin : Site Reference ID/Investigator# 30762

Kaletra in Combination With Antiretroviral Agents

Berlin : Site Reference ID/Investigator# 28260

Kaletra in Combination With Antiretroviral Agents

Berlin : Site Reference ID/Investigator# 30764

Kaletra in Combination With Antiretroviral Agents

Berlin : Site Reference ID/Investigator# 28185

Kaletra in Combination With Antiretroviral Agents

Berlin : Site Reference ID/Investigator# 28249

Kaletra in Combination With Antiretroviral Agents

Berlin : Site Reference ID/Investigator# 28243

Kaletra in Combination With Antiretroviral Agents

Berlin : Site Reference ID/Investigator# 63682

Kaletra in Combination With Antiretroviral Agents

Berlin : Site Reference ID/Investigator# 28229

Kaletra in Combination With Antiretroviral Agents

Berlin : Site Reference ID/Investigator# 28199

Kaletra in Combination With Antiretroviral Agents

Berlin : Site Reference ID/Investigator# 30763

Kaletra in Combination With Antiretroviral Agents

Berlin : Site Reference ID/Investigator# 28205

Kaletra in Combination With Antiretroviral Agents

Berlin : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Berlin : CHARITÉ Berlin

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Berlin : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Berlin : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Berlin : Gemeinschaftspraxis Jessen-Jessen-Stein

Strategic Timing of Antiretroviral Treatment

Berlin : EPIMED-Gesellschaft fuer epidemiologische und klinische Forschung in der MedizinmbH

Strategic Timing of Antiretroviral Treatment

Berlin : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Berlin : Site Reference ID/Investigator# 28559

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 28494

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 28567

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 29271

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 28503

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 28522

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 28504

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 32383

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 59472

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 28518

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 28569

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 28496

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 47146

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 28485

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 28514

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 28486

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 29147

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 28484

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 29154

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 28557

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Site Reference ID/Investigator# 32384

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Berlin : Charite Campus, Virchow-Klinikum Medizinische Klinik mit Schwerpunkt Infektiologie Station 59 (Suedring 11) Augustenburger Platz 1 Updated

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

Berlin : EIPMED - Gesellschaft fűr epidemiologische und klinische Forschung in der Medizin mbH Rubensstrasse 125 Updated

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

Bochum : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Bochum : Site Reference ID/Investigator# 28488

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Bonn :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Bonn :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Bonn : University of Bonn

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Bonn : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Bonn : Medizinische Universitaetsklinik - Bonn, Immunologische Ambulanz CRS

Strategic Timing of Antiretroviral Treatment

Bonn : Site Reference ID/Investigator# 28562

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Bonn : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Bremen : Site Reference ID/Investigator# 28224

Kaletra in Combination With Antiretroviral Agents

Bremen : Site Reference ID/Investigator# 29269

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Bremen : Site Reference ID/Investigator# 59469

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Cologne : Site Reference ID/Investigator# 28252

Kaletra in Combination With Antiretroviral Agents

Cologne : University of Cologne

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Cologne : Klinik I fur Innere Medizin der Universitat zu Koeln, Studienbuero fuer Infektiologie u. HIV CRS

Strategic Timing of Antiretroviral Treatment

Cologne : Site Reference ID/Investigator# 28571

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Cologne : Site Reference ID/Investigator# 29262

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Cologne : Site Reference ID/Investigator# 28495

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Cologne : Site Reference ID/Investigator# 28554

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Cologne : Site Reference ID/Investigator# 28563

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Dortmund :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Dortmund : Site Reference ID/Investigator# 28223

Kaletra in Combination With Antiretroviral Agents

Dortmund : Site Reference ID/Investigator# 28184

Kaletra in Combination With Antiretroviral Agents

Dortmund : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Dortmund : Klinikum Dortmund gGmbH

Strategic Timing of Antiretroviral Treatment

Dortmund : Site Reference ID/Investigator# 28516

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Dortmund : Site Reference ID/Investigator# 47142

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Dortmund : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Dresden :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Dresden : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Duesseldorf :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Duesseldorf : Site Reference ID/Investigator# 63685

Kaletra in Combination With Antiretroviral Agents

Duesseldorf : Site Reference ID/Investigator# 28250

Kaletra in Combination With Antiretroviral Agents

Duesseldorf : Site Reference ID/Investigator# 28188

Kaletra in Combination With Antiretroviral Agents

Duesseldorf : Universitaetsklinikum Duesseldorf

Strategic Timing of Antiretroviral Treatment

Duesseldorf : Site Reference ID/Investigator# 28491

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Duesseldorf : Site Reference ID/Investigator# 28547

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Duisburg : Site Reference ID/Investigator# 28231

Kaletra in Combination With Antiretroviral Agents

Duisburg : Site Reference ID/Investigator# 28524

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Dusseldorf : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Erlangen :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Erlangen : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Erlangen : Universitaetsklinikum Erlangen

Strategic Timing of Antiretroviral Treatment

Essen : Site Reference ID/Investigator# 28194

Kaletra in Combination With Antiretroviral Agents

Essen : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Essen : Klinik fur Dermatologie, Venerologie, Allergologie

Strategic Timing of Antiretroviral Treatment

Frankfurt :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Frankfurt :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Frankfurt : Site Reference ID/Investigator# 28227

Kaletra in Combination With Antiretroviral Agents

Frankfurt : Site Reference ID/Investigator# 28233

Kaletra in Combination With Antiretroviral Agents

Frankfurt : German Competence Network

Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

Frankfurt : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Frankfurt : Johann Wolfgang Goethe - University Hospital, Infektionsambulanz CRS

Strategic Timing of Antiretroviral Treatment

Frankfurt : Site Reference ID/Investigator# 29270

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Frankfurt : Site Reference ID/Investigator# 28520

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Frankfurt : Site Reference ID/Investigator# 28545

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Frankfurt : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Frankfurt am Main : Site Reference ID/Investigator# 54202

Kaletra in Combination With Antiretroviral Agents

Frankfurt am Main : Johann Wolfgang Goethe-Universität

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Frankfurt am Main : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Frankfurt Am Main : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Frankfurt am Main : Site Reference ID/Investigator# 29260

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Freiburg :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Freiburg : Site Reference ID/Investigator# 28258

Kaletra in Combination With Antiretroviral Agents

Freiburg : Site Reference ID/Investigator# 28246

Kaletra in Combination With Antiretroviral Agents

Freiburg : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Freiburg : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Freiburg : Site Reference ID/Investigator# 29266

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Freiburg : Site Reference ID/Investigator# 28564

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Freiburg : Site Reference ID/Investigator# 28550

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Fuerth : Site Reference ID/Investigator# 28251

Kaletra in Combination With Antiretroviral Agents

Fuerth : Site Reference ID/Investigator# 28570

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Giessen : Site Reference ID/Investigator# 28193

Kaletra in Combination With Antiretroviral Agents

Giessen : Site Reference ID/Investigator# 28196

Kaletra in Combination With Antiretroviral Agents

Giessen : Site Reference ID/Investigator# 28498

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Haar : Merck Sharp & Dohme GmbH

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Halle : Site Reference ID/Investigator# 28261

Kaletra in Combination With Antiretroviral Agents

Hamburg :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Hamburg :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Hamburg : Site Reference ID/Investigator# 47154

Kaletra in Combination With Antiretroviral Agents

Hamburg : Site Reference ID/Investigator# 28259

Kaletra in Combination With Antiretroviral Agents

Hamburg : Site Reference ID/Investigator# 28256

Kaletra in Combination With Antiretroviral Agents

Hamburg : Site Reference ID/Investigator# 28202

Kaletra in Combination With Antiretroviral Agents

Hamburg : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Hamburg : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Hamburg : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Hamburg : University Medical Centre Hamburg-Eppendorf

Strategic Timing of Antiretroviral Treatment

Hamburg : ICH Study Center

Strategic Timing of Antiretroviral Treatment

Hamburg : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Hamburg : Site Reference ID/Investigator# 28566

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Hamburg : Site Reference ID/Investigator# 28544

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Hamburg : Site Reference ID/Investigator# 29272

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Hamburg : Site Reference ID/Investigator# 29261

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Hamburg : Site Reference ID/Investigator# 32382

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Hamburg : Site Reference ID/Investigator# 28515

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Hamburg : Site Reference ID/Investigator# 29267

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Hamburg : Site Reference ID/Investigator# 32386

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Hamburg : Site Reference ID/Investigator# 28513

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Hamburg : Site Reference ID/Investigator# 28549

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Hamburg : Site Reference ID/Investigator# 28507

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Hamburg : Site Reference ID/Investigator# 28489

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Hamburg : University Medical Center Hamburg-Eppendorf Updated

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

Hannover : Site Reference ID/Investigator# 28248

Kaletra in Combination With Antiretroviral Agents

Hannover : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Hannover : Site Reference ID/Investigator# 28568

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Hanover : Site Reference ID/Investigator# 28230

Kaletra in Combination With Antiretroviral Agents

Hanover : Medizinische Hochschule Hannover

Strategic Timing of Antiretroviral Treatment

Hanover : Site Reference ID/Investigator# 29273

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Hanover : Site Reference ID/Investigator# 28523

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Heidelberg : Universitaetsklinikum Heidelberg

Strategic Timing of Antiretroviral Treatment

Heidelberg : Site Reference ID/Investigator# 47145

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Karlsruhe : Site Reference ID/Investigator# 28551

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Koblenz : Site Reference ID/Investigator# 47153

Kaletra in Combination With Antiretroviral Agents

Koblenz : Site Reference ID/Investigator# 28561

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Koeln : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Koeln : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Köln :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Köln : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Köln : Klinik I für Innere Medizin Klinikum Der Universität zu Köln Updated

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

Krefeld : Site Reference ID/Investigator# 18221

Kaletra in Combination With Antiretroviral Agents

Krefeld : Site Reference ID/Investigator# 28483

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Leipzig : Site Reference ID/Investigator# 47144

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Leipzig : Site Reference ID/Investigator# 28482

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Ludwigshafen : Site Reference ID/Investigator# 47151

Kaletra in Combination With Antiretroviral Agents

Ludwigshafen : Site Reference ID/Investigator# 28493

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Luebeck : Site Reference ID/Investigator# 28192

Kaletra in Combination With Antiretroviral Agents

Luebeck : Site Reference ID/Investigator# 28500

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Magdeburg :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Magdeburg : Site Reference ID/Investigator# 54278

Kaletra in Combination With Antiretroviral Agents

Magdeburg : Site Reference ID/Investigator# 59468

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Mainz :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Mainz : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Mainz : Site Reference ID/Investigator# 28565

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Mainz : Site Reference ID/Investigator# 28574

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Mannheim :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Mannheim : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Muenchen : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Muenchen : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Muenster : Site Reference ID/Investigator# 28197

Kaletra in Combination With Antiretroviral Agents

Muenster : Site Reference ID/Investigator# 28560

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Muenster : Site Reference ID/Investigator# 28492

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Muenster : Site Reference ID/Investigator# 28490

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Munchen : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

München :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

München : University München

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Munich : Site Reference ID/Investigator# 28235

Kaletra in Combination With Antiretroviral Agents

Munich : Site Reference ID/Investigator# 28200

Kaletra in Combination With Antiretroviral Agents

Munich : Site Reference ID/Investigator# 28225

Kaletra in Combination With Antiretroviral Agents

Munich : Site Reference ID/Investigator# 28242

Kaletra in Combination With Antiretroviral Agents

Munich : Klinikum der Universitaet Muenchen

Strategic Timing of Antiretroviral Treatment

Munich : Site Reference ID/Investigator# 28517

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Munich : Site Reference ID/Investigator# 28519

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Munich : Site Reference ID/Investigator# 28505

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Munich : Site Reference ID/Investigator# 28548

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Munich : Site Reference ID/Investigator# 28556

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Munich : Site Reference ID/Investigator# 28508

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Nuremberg : Site Reference ID/Investigator# 81614

Kaletra in Combination With Antiretroviral Agents

Nuremberg : Site Reference ID/Investigator# 5346

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Oldenburg : Site Reference ID/Investigator# 28555

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Osnabrueck : Site Reference ID/Investigator# 28240

Kaletra in Combination With Antiretroviral Agents

Osnabrueck : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Osnabrueck : Site Reference ID/Investigator# 28553

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Regensburg :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Regensburg : Site Reference ID/Investigator# 47149

Kaletra in Combination With Antiretroviral Agents

Regensburg : University Clinic Regensburg, Klinik I Fuer Innere Medizin

Strategic Timing of Antiretroviral Treatment

Regensburg : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Rostock : Site Reference ID/Investigator# 59467

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Saarbruecken : Site Reference ID/Investigator# 28506

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Schkeuditz : Site Reference ID/Investigator# 63686

Kaletra in Combination With Antiretroviral Agents

Schkeuditz : Site Reference ID/Investigator# 59471

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Stuttgart :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Stuttgart : Site Reference ID/Investigator# 28257

Kaletra in Combination With Antiretroviral Agents

Stuttgart : Site Reference ID/Investigator# 28239

Kaletra in Combination With Antiretroviral Agents

Stuttgart : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Stuttgart : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Stuttgart : Site Reference ID/Investigator# 29265

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Stuttgart : Site Reference ID/Investigator# 28552

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Troisdorf : Site Reference ID/Investigator# 28572

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Tübingen : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Tuebingen : Site Reference ID/Investigator# 28511

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Ulm :

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Wiesbaden : Site Reference ID/Investigator# 29264

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Wuerzburg : University of Wuerzburg, Medizinische Poliklinik, Schwerpunkt Hepatologie/Infektologie CRS

Strategic Timing of Antiretroviral Treatment

Wuppertal : Site Reference ID/Investigator# 28234

Kaletra in Combination With Antiretroviral Agents

Wuppertal : Site Reference ID/Investigator# 28546

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Würzburg :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Athens : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Athens : Hippokration University General Hospital of Athens

Strategic Timing of Antiretroviral Treatment

Athens : Syngros Hospital

Strategic Timing of Antiretroviral Treatment

Athens : Evangelismos General Hospital

Strategic Timing of Antiretroviral Treatment

Athens : Korgialenio-Benakio Hellenic Red Cross

Strategic Timing of Antiretroviral Treatment

View More »

Athens : Attikon University General Hospital

Strategic Timing of Antiretroviral Treatment

Patras : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Piraeus : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Thessaloniki : AHEPA University Hospital

Strategic Timing of Antiretroviral Treatment

Chennai : GSK Investigational Site

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Kolkata : GSK Investigational Site

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Mumbai : GSK Investigational Site

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Pune : GSK Investigational Site

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Dublin : St James's Hospital Dublin

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Dublin : Mater Hospital and UCD

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Dublin : Mater Misericordiae University Hospital

Strategic Timing of Antiretroviral Treatment

Dublin : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Be'er-Sheva : Site Reference ID/Investigator# 27833

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Haifa : Rambam Medical Center

Strategic Timing of Antiretroviral Treatment

Haifa : Site Reference ID/Investigator# 17549

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Jerusalem : Site Reference ID/Investigator# 27830

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Kfar Saba : Site Reference ID/Investigator# 27832

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

View More »

Rechovot : Site Reference ID/Investigator# 27829

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Tel Aviv : Tel Aviv Sourasky Medical Center

Strategic Timing of Antiretroviral Treatment

Tel-Hashomer : Site Reference ID/Investigator# 27831

Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Bari : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Bergamo :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Bologna : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Brescia : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Busto Arsizio (Va) : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

View More »

Firenze : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Florence : Italian Register for HIV-infection in Children

Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

Genova : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Milan : Infectious Diseases Department Fondazione Centro San Raffaele

Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression

Milan : San Raffaele Hospital Dep. Infectious Diseases

Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy

Milan : San Raffaele Hospital, Dep. Infectious Diseases

Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy

Milan : Ospedale San Raffaele S.r.l.

Strategic Timing of Antiretroviral Treatment

Milano : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Milano : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Modena : Policlinico di Modena, Divisione di Malattie Infettive

A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

Modena : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Modena : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Monza : Azienda Ospedaliera San Gerardo, Divisione di Malattie Infettive

A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

Napoli : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Padova : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Palermo : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Pavia : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Pescara : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Roma : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Roma : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Rome : IFO - S. Gallicano, Dermatologia Infettiva

A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

Rome : IRCSS

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Rome : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Rome : Lazzaro Spallanzani IRCSS

Strategic Timing of Antiretroviral Treatment

Torino : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Torino : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Varese : Ospedale di Circolo and Fondazione Macchi

Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients

Shinjuku-ku, Tokyo : National Center for Global Health and Medicine AIDS Clinical Center

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

Dae-Gu :

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence

Dae-Gu :

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista

Incheon : GSK Investigational Site

ZIAGEN® Post-marketing Surveillance

Seoul : Seoul National University Hospital

Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients

Seoul : MSD Korea LTD

Stocrin Re-examination Study (0831-028 AM1)

Luxembourg : Centre Hospitalier de Luxembourg

Strategic Timing of Antiretroviral Treatment

Blantyre : College of Med. JHU CRS

Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding

Lilongwe : University of North Carolina Lilongwe CRS

Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding

Kuala Lumpur : University Malaya Medical Centre

Strategic Timing of Antiretroviral Treatment

Bamako : Serefo/Cesac Mali

Strategic Timing of Antiretroviral Treatment

Df : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Guadalajara : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Merida : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Oaxaca : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Tlalpan : INCMNSZ

Strategic Timing of Antiretroviral Treatment

Casablanca : University Hospital Centre Ibn Rochd

Strategic Timing of Antiretroviral Treatment

Amsterdam : Academic Medical Center

Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)

Amsterdam : Onze Lieve Vrouwe Gasthuis

RAltegravir Switch STudy: Effects on Endothelial Recovery

Haarlem : Merck Sharp & Dohme BV

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Nijmegen : Radboud University Nijmegen Medical Centre

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Rotterdam : Erasmus Medical Center

Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)

View More »

Rotterdam : Erasmus Medical Center Rotterdam

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Utrecht : University Medical Center Utrecht

RAltegravir Switch STudy: Effects on Endothelial Recovery

Abuja : Institute of Human Virology-Nigeria (IHVN)

Strategic Timing of Antiretroviral Treatment

Ibadan : Department of Medical Microbiology & Parasitology, College of Medicine, University of Ibadan

Trial of SAVVY Vaginal Gel and HIV in Nigeria

Lagos : Nigerian Institute of Medical Research

Trial of SAVVY Vaginal Gel and HIV in Nigeria

Oslo : Oslo University Hospital, Ullevål

Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART

Oslo : Oslo University Hospital, Ulleval

Strategic Timing of Antiretroviral Treatment

Lima : Hospital Nacional Edgardo Rebagliati Martins

Strategic Timing of Antiretroviral Treatment

Lima : Via Libre

Strategic Timing of Antiretroviral Treatment

Lima : IMPACTA San Miguel

Strategic Timing of Antiretroviral Treatment

Lima : Hospital Nacional Guillermo Almenara Irigoyen

Strategic Timing of Antiretroviral Treatment

Lima : Asociacion Civil Impacta Salud y Educacion

Strategic Timing of Antiretroviral Treatment

Bialystok : Boehringer Ingelheim Investigational Site 8

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bialystok : Boehringer Ingelheim Investigational Site 7

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bialystok : Wojewodzki Szpital Specjalistyczny

Strategic Timing of Antiretroviral Treatment

Bydgoszcz : Boehringer Ingelheim Investigational Site 9

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bydgoszcz : Boehringer Ingelheim Investigational Site 10

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

View More »

Chorzów : Boehringer Ingelheim Investigational Site 13

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Chorzów : Boehringer Ingelheim Investigational Site 12

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Chorzów : Boehringer Ingelheim Investigational Site 11

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Chorzów : Boehringer Ingelheim Investigational Site 14

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Gda?sk : Boehringer Ingelheim Investigational Site 15

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Gda?sk : Boehringer Ingelheim Investigational Site 17

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Gda?sk : Boehringer Ingelheim Investigational Site 16

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Kraków : Boehringer Ingelheim Investigational Site 19

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Kraków : Boehringer Ingelheim Investigational Site 18

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Pozna? : Boehringer Ingelheim Investigational Site 20

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Warsaw : Wojewodzki Szpital Zakazny

Strategic Timing of Antiretroviral Treatment

Warszawa : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Wroc?aw : Boehringer Ingelheim Investigational Site 21

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Wroc?aw : Boehringer Ingelheim Investigational Site 23

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Wroc?aw : Boehringer Ingelheim Investigational Site 22

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Wroc?aw : Boehringer Ingelheim Investigational Site 24

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Wroclaw : EMC Instytut Medyczny SA

Strategic Timing of Antiretroviral Treatment

Zielona Góra : Boehringer Ingelheim Investigational Site 26

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Zielona Góra : Boehringer Ingelheim Investigational Site 25

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Aveiro : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Barreiro : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Faro : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Lisboa : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Lisboa : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

View More »

Lisbon : Hospital Curry Cabral

Strategic Timing of Antiretroviral Treatment

Lisbon : Hospital de Santa Maria

Strategic Timing of Antiretroviral Treatment

Lisbon : Hospital de Egas Moniz

Strategic Timing of Antiretroviral Treatment

Oporto : Hospital Joaquim Urbano

Strategic Timing of Antiretroviral Treatment

Porto : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Porto : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Pragal : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Santarem : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Sao Martinho do Bispo : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Vila Nova de Gaia : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Carolina : Merck Sharp & Dohme (I.A.) Corp.

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Ponce : Call for Information (Investigational Site 0052)

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Ponce : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Rio Piedras : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Rio Piedras : San Juan Hospital

Strategic Timing of Antiretroviral Treatment

View More »

San Juan : University of Puerto Rico Pediatric HIV/AIDS CRS (6601)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

San Juan : San Juan City Hosp. PR NICHD CRS (5031)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

San Juan : Puerto Rico-AIDS CRS (5401)

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

San Juan : HOPE Clinical Research Updated

Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

San Juan : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

San Juan : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

San Juan : Puerto Rico-AIDS Clinical Trials Unit (PR-ACTU)

Strategic Timing of Antiretroviral Treatment

San Juan : University of Puerto Rico Pediatric Research Site

Strategic Timing of Antiretroviral Treatment

San Juan : Hope Clinical Research

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

San Juan : HOPE Clinical Research

Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults

San Juan Pr :

A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women

Santurce : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Bacau : Boehringer Ingelheim Investigational Site 61

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Brasov : Boehringer Ingelheim Investigational Site 64

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Brasov : Boehringer Ingelheim Investigational Site 62

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Brasov : Boehringer Ingelheim Investigational Site 63

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucharest : Merck Sharp & Dohme Romania SRL

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

View More »

Bucharest : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Bucharest : Victor Babes Hospital

Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

Bucuresti : Boehringer Ingelheim Investigational Site 28

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 44

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 30

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 33

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 42

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 38

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 52

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 51

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 31

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 36

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 46

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 34

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 27

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 50

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 47

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 53

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 49

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 35

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 29

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 45

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 37

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 43

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 39

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 54

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 40

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 32

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 41

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 48

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Bucuresti : Boehringer Ingelheim Investigational Site 55

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Constanta : Boehringer Ingelheim Investigational Site 57

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Constanta : Boehringer Ingelheim Investigational Site 59

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Constanta : Boehringer Ingelheim Investigational Site 58

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Giurgiu : Boehringer Ingelheim Investigational Site 56

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Ploiesti : Boehringer Ingelheim Investigational Site 60

Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice

Kaluga : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Loshkar-Ola : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Moscow : Merck Sharp & Dohme IDEA, Inc.

A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With HIV-1

Moscow : Central Research Institute for Epidemiology

Co-receptor Tropism Determination of HIV-1 Subtype A Spread in the Russian Federation Using V3-based Genotyping Tools

Moscow : Central Research Institute of Epidemiology

Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients

View More »

Moscow : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Perm : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Saint-Petersburg : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Smolensk : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

St Petersburg : Updated

Telaprevir Open-Label Study in Co-Infected Patients

St. Petersburg : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

St. Petersburg : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

St.petersburg : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

St.petersburg : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Toliatti : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Volgograd : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Dakar : Clinical Research and Training Center, Fann Hospital

Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)

Benoni : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Bloemfontein :

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents

Bloemfontein : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Bloemfontein : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Cape Town : Stellenbosch University CRS (8950)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

View More »

Cape Town : Desmond Tutu HIV Research Centre

Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Cape Town : Desmond Tutu HIV Foundation Clinical Trials Unit

Strategic Timing of Antiretroviral Treatment

Cape Town : Stellenbosch Univ. CRS

Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding

Diepkloof : Perinatal HIV Research UNIT

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

Dundee : GSK Investigational Site

An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc

Dundee : Mpati Medical Center

Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Durban : University KZN

Strategic Timing of Antiretroviral Treatment

Durban : DICTU

Strategic Timing of Antiretroviral Treatment

Durban : Durban Paediatric HIV CRS

Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding

Ga-Rankuwa : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Gaunteng : Infectious Diseases Clinincal Trial Unit

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

Gauteng : Perinatal HIV Research Unit

Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Johannesburg : Harriet Shezi Children's Clinic (8051)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Johannesburg : Soweto IMPAACT CRS (8052)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Johannesburg : Clinical HIV Research Unit

Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Johannesburg : CHRU

Strategic Timing of Antiretroviral Treatment

Johannesburg : Shandukani Research CRS

Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding

Johannesburg, Gauteng : Soweto IMPAACT CRS

Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding

Newtown :

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents

Parrow Valley : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Port Elizabeth : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Pretoria :

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents

Pretoria : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Pretoria : 1 Military Hospital

Strategic Timing of Antiretroviral Treatment

Pretoria N/A :

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents

Soweto : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Umlazi : CAPRISA Umlazi CRS

Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding

A Coru : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Alcala de Henares : Hospital Universitario Principe de Asturias

Strategic Timing of Antiretroviral Treatment

Alcalá de Henares : Hospital Príncipe de Asturias

HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir

Alcalá de Henares : Hospital Príncipe de Asturias

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Alicante : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

View More »

Alicante : Hospital General de Alicante

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Asturias : H. Universitario Central de Asturias

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Badalona : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Badalona : Hospital Universitari Germans Trias i Pujol, Badalona

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Badalona : H. Germans Trias i Pujol

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Badalona : Hospital Universitari Germans Trias I Pujol, HIV Unit and Retrovirology Lab CRS

Strategic Timing of Antiretroviral Treatment

Badalona : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Barcelona :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Barcelona : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Barcelona : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Barcelona : Spanish Perinatal Cohort

Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

Barcelona : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Barcelona : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Barcelona : Hospital Vall d'Hebrón

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Barcelona : Hospital Santa Creu i Sant Pau

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Barcelona : Hospital Clinico de Barcelona CRS

Strategic Timing of Antiretroviral Treatment

Barcelona : Hospital del Mar

Strategic Timing of Antiretroviral Treatment

Barcelona : Hospital de la Santa Creu i Sant Pau

Strategic Timing of Antiretroviral Treatment

Barcelona : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Basurto : Hospital de Basurto

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Cadiz : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Cordoba : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Cordoba : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Córdoba : Hospital Reina Sofía

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

El Ferrol : Hospital Arquitecto Marcide

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Elche : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Elche : Hospital de Elche

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Esplugues de Llobregat : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Granada : Hospital Universitario Virgen de las Nieves Granada; Médico Adjunto del Servicio de Medicina Interna

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Granada : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Granada : Hospital Clínico San Cecilio

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Granada : Hospital Virgen de las Nieves

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Granada : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Granollers : Hospital General de Granollers

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Granollers : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Guadalajara : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Huelva : H. Juan Ramón Jiménez

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Jerez de la Frontera : Hospital de Jerez

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Jerez de la Frontera : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

La Coruña : Hospital Juan Canalejo

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Leganes : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Leganés : Hospital Severo Ochoa

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Logro : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Logrono : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Logroño : H. San Pedro

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Madrid : Merck Sharp and Dohme de Espana S.A.

A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007 AM9)

Madrid : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Madrid : Hospital Doce de Octubre

HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir

Madrid : Hospital La Paz

HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir

Madrid : Hospital Clínico San Carlos

HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir

Madrid : Hospital Gregorio Marañón

HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir

Madrid : Hospital Ramón y Cajal

HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir

Madrid : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Madrid : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Madrid : Madrid Paediatric HIV Cohort

Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

Madrid : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Madrid : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Madrid : Hospital Doce de Octubre

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Madrid : Hospital Gregorio Marañón

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Madrid : Hospital La Paz

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Madrid : H. Universitario Infanta Leonor

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Madrid : Hospital Ramón y Cajal

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Madrid : H. Clinico San Carlos

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Madrid : Hospital La Princesa, Internal Medicine and Infectious Disease Service CRS

Strategic Timing of Antiretroviral Treatment

Madrid : Hospital La Paz

Strategic Timing of Antiretroviral Treatment

Madrid : Hospital Clinico San Carlos

Strategic Timing of Antiretroviral Treatment

Madrid : Hospital Universitario Doce de Octubre

Strategic Timing of Antiretroviral Treatment

Madrid : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Malaga : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Malaga : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Málaga : Hospital Virgen de la Victoria

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Mallorca : H. Universitario Son Espases

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Marbella : Hospital Costa del Sol

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Marbella : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Mataro : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Mataro : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Mataró : Hospital de Mataró

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Mostoles : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Mostoles, Madrid : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Móstoles, Madrid : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Pamplona : Hospital de Navarra

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

San Sebastian : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

San Sebastián : Hospital Donostia

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Santander : Hospital Marqués de Valdecilla

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Santiago de Compostela : Complexo Hospitalario Universitario de Santiago

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Santiago de Compostela : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Sevilla : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Sevilla : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

Sevilla : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Tarragona : Hospital de Santa Tecla

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Tarragona : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Tenerife, Canary Island : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Terrassa : Hospital Universitari Mutua Terrassa

Strategic Timing of Antiretroviral Treatment

Valencia : GSK Investigational Site

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

Valencia : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Valencia : Hospital La Fe

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Valencia : Hospital Universitario y Politecnico La Fe

Strategic Timing of Antiretroviral Treatment

Valencia : Hospital General Universitario de Valencia

Strategic Timing of Antiretroviral Treatment

Valencia : Local Institution

Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting

Vigo : Hospital Xeral Cíes

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Vigo : Complejo Hospitalario Xeral Cies

Strategic Timing of Antiretroviral Treatment

Villajoyosa : Hospital Marina Baixa

Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy

Gothenburg : Sahlgrenska University Hospital

Strategic Timing of Antiretroviral Treatment

Malmo : Skane University Hospital

Strategic Timing of Antiretroviral Treatment

Bale : Universitätsspital Basel Klinik für Infektiologie & Spitalhygiene

Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs

Basel : Swiss Mother and Child HIV Cohort

Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

Basel : University Hospital Basel

Strategic Timing of Antiretroviral Treatment

Bern : Bern University Hospital

Strategic Timing of Antiretroviral Treatment

Berne : Inselspital PKT2B / Poliklinik für Infektiologie

Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs

View More »

Geneva : HUG /Division des Maladies infectieuses Unité VIH/SIDA

Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs

Geneva : Unite VIH/SIDA Geneva

Strategic Timing of Antiretroviral Treatment

La Chaux-de-Fonds : Hôpital Neuchâtelois - La Chaux-de-Fonds Service des Maladies infectieuses

Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs

Lausanne : CHUV / Service des maladies infectieuses Médecine 2

Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs

St Gallen : Kantonsspital / Infektiologie und Spitalhygiene Departement Innere Medizin

Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs

Zurich : Universitätsspital Zürich Division of Infectious Diseases and Hospital Epidemiology Department of Internal Medicine

Prospective Evaluation of Etravirine for HIV-infected Patients in Need of Lipid-lowering Drugs

Zurich : University Hospital Zurich

Raltegravir in the Swiss HIV Cohort Study

Zurich : University Hospital Zurich

Strategic Timing of Antiretroviral Treatment

IDC Research Offices : Kilimanjaro Christian Medical CRS (12901)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Bangkok :

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents

Bangkok : Bhumibol Adulyadej Hospital (8355)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Bangkok : Siriraj Hospital Mahidol University CRS (8251)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Bangkok : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Bangkok : Thai Red Cross AIDS Research Centre

Antiretroviral Therapy for Acute HIV Infection

View More »

Bangkok : GSK Investigational Site

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Bangkok : The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)

Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Bangkok : Ramathibodi Hospital

Strategic Timing of Antiretroviral Treatment

Bangkok : Chulalongkorn University Hospital

Strategic Timing of Antiretroviral Treatment

Bangkok noi : Pfizer Investigational Site

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Bangkok Noi : Siriraj Hospital

Strategic Timing of Antiretroviral Treatment

Chantaburi : Prapokklao Hospital CRS (8354)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Chiang Mai : Chaing Mai University (20101)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Chiang Mai : Research Institute for Health Sciences (RIHES)

Strategic Timing of Antiretroviral Treatment

Chiang Mai : Sanpatong Hospital

Strategic Timing of Antiretroviral Treatment

Chiang Rai : Chiang Rai Regional Hospital CRS (8352)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Chiangmai : GSK Investigational Site

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Chiangrai : Chiangrai Prachanukroh Hospital

Strategic Timing of Antiretroviral Treatment

Chonburi : Chonburi Hosp. CRS (8356)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Chonburi : Chonburi Regional Hospital

Strategic Timing of Antiretroviral Treatment

Khon Kaen :

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents

Khon Kaen : GSK Investigational Site

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Khon Kaen : Khon Kaen University, Srinagarind Hospital

Strategic Timing of Antiretroviral Treatment

Nonthaburi : Bamrasnaradura Institute

Strategic Timing of Antiretroviral Treatment

Pathumwan : The Thai Red Cross AIDS Research Centre

Bone Health and Vitamin D Status

Phayao : Phayao Provincial Hospital CRS (8353)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Entebbe : MRC UVRI Uganda Research Unit on AIDS

Strategic Timing of Antiretroviral Treatment

Kampala :

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents

Kampala : Makerere University - JHU Research Collaboration (30293)

A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Kampala : Joint Clinical Research Center (JCRC)

Strategic Timing of Antiretroviral Treatment

Kampala : Makerere University- JHU Research Collaboration {MUJHU CARE LTD} CRS

Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding

Kiev :

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents

Belfast : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Belfast : Belfast Health and Social Care Trust (RVH)

Strategic Timing of Antiretroviral Treatment

Birmingham : Local Institution

Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)

Birmingham : Birmingham Heartlands Hospital

Strategic Timing of Antiretroviral Treatment

Birmingham : Queen Elizabeth Hospital Birmingham

Strategic Timing of Antiretroviral Treatment

View More »

Birmingham : Heart of England NHS Foundation Trust

The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects

Bournemouth : Royal Bournemouth Hospital

Strategic Timing of Antiretroviral Treatment

Brighton : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Brighton : Brighton and Sussex University Hospitals NHS Trust

Strategic Timing of Antiretroviral Treatment

Cottingham : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Coventry : Coventry and Warwickshire NHS partnership Trust

Strategic Timing of Antiretroviral Treatment

Crumpsall, Manchester : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Edinburgh : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Glasgow :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Gloucester : Gloucestershire Royal Hospital

Strategic Timing of Antiretroviral Treatment

Leicester : Leicester Royal Infirmary

Strategic Timing of Antiretroviral Treatment

Liverpool : Updated

Telaprevir Open-Label Study in Co-Infected Patients

London :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

London : St. George's Hospital, London

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

London : C&W Hospital, London

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

London : St Mary's Hospital, London

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

London : European Collaborative Study

Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

London : Collaborative HIV Paediatric Study

Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

London : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

London : Local Institution

Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus

London : South London Healthcare NHS Trust

Strategic Timing of Antiretroviral Treatment

London : St. George's Healthcare NHS Trust

Strategic Timing of Antiretroviral Treatment

London : Royal Free London NHS Foundation Trust

Strategic Timing of Antiretroviral Treatment

London : Guy's and St.Thomas' NHS Foundation Trust

Strategic Timing of Antiretroviral Treatment

London : Barts Health NHS Trust

Strategic Timing of Antiretroviral Treatment

London : University College London Medical School

Strategic Timing of Antiretroviral Treatment

London : Chelsea and Westminster Hospital

Strategic Timing of Antiretroviral Treatment

London : Imperial College Healthcare NHS Trust

Strategic Timing of Antiretroviral Treatment

London : Updated

Telaprevir Open-Label Study in Co-Infected Patients

London : St. Mary's Hospital

The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects

Manchester : North Manchester General Hospital

Strategic Timing of Antiretroviral Treatment

Middlesbrough : The James Cook University Hospital

Strategic Timing of Antiretroviral Treatment

Newcastle upon Tyne : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Plymouth : Updated

Telaprevir Open-Label Study in Co-Infected Patients

Reading : Royal Berkshire Hospital

Strategic Timing of Antiretroviral Treatment

Sally Oak : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Sheffield : Sheffield Teaching Hospital NHS Foundation Trust

Strategic Timing of Antiretroviral Treatment

Shoreham, West Sussex : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Stoke on Trent, Staffordshire : Pfizer Investigational Site

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Sussex :

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects

Chitungwiza : St Mary's CRS

Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding

Chitungwiza : Seke North CRS

Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding

Harare : UZ-Parirenyatwa CRS

Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding